viewTissue Regenix Group PLC

Proactive pitches up in London and Dublin next week

The Proactive big top pitches up next week in Dublin and London with a very excitig clutch of companies - all with growth potential.


The Proactive big top pitches up next week in Dublin and London with a very exciting clutch of companies - all with growth potential.

First off, we are in Dublin on Tuesday, October 29, showcasing Advanced Oncotherapy (LON:AVO), Zamano (LON: ZMNO), Alliance Pharma (LON:APH) and Tissue Regenix (LON:TRX).

Register your place at this event HERE.

Advanced Oncotherapy specialises in internationally endorsed technology for advanced radiotherapy to treat common and rare cancers.

A deal recently to acquire ADAM, a company spin-off from CERN, the European Organization for Nuclear Research that is striving to uncover the secrets of the universe, is part of the plan. 

ADAM brought with it some proprietary technology called Linac Image Guided Hadron Technology - or LIGHT – that represents the next generation of proton beam therapy. 

This disruptive technology has an order pipeline in excess of £200mln and an anticipated net profit margin of 10%.

Karen Bullivant, the head of marketing, is joining us to explain the science and growth path for the company.

Meanwhile, Zamano (LON:ZMNO) is profitable, cash generative and virtually debt-free.

The company is at the centre of a large and growing market, and even its core franchises in Ireland and the UK have potential for expansion, while the international scope of the business could be huge.

Zamano’s entertainment portfolio encompasses music and video streaming, quizzes, sport, games and alerts that are charged via micro-payments.

The company has a new product – the splendidly named Messagehero – that is a web text-messaging platform for small businesses. It is high-margin, but is also expected to be a volume business, given that premium message volumes grew to around 240bn last year and are tipped to burst through the one trillion barrier by 2017.

It is fair to say that the company has a chequered past, but since 2011 new management has turned the business around, paying down debt while still investing in the business. It seems the market has yet to notice; the company is trading on less than three times 2012’s earnings per share.

Alliance Pharma has been around a long time, starting life as a speciality pharmaceutical company in 1998. 

Its stock in trade is focusing on the acquisition of established niche medicines, typically in areas where there is limited competition.

This is no high risk/high reward pharmaceutical company navigating a flagship product through the labyrinth of the medical regulatory process; it is a profitable, cash generative company that pays a dividend.

The company recently agreed a new enlarged debt package on better terms that give it access to £55mln and for a company with a strong track record of making canny acquisitions, the increased firepower should come in handy.

Speaking to Proactive Investors earlier this year, chief executive John Dawson said acquisition opportunities are always on the table.

Tissue Regenix (LON:TRX) is an international regenerative medical devices company that uses animal or human tissue to replace damaged or worn out parts of the human body.

Its proprietary platform, known as dCELL, can be used to make 20-30 different products. The group's largest area of focus is wound care, while the company is also developing applications in cardiac and orthopaedics markets.

The market for human therapeutic products employing tissue engineering ranks as one of the most rapidly growing sectors within the medical products market.

Once regulatory approvals have been obtained, Tissue Regenix will look to license dCELL Technology to third parties and enter co-marketing and/or distribution agreements.

The company has achieved a number of critical milestones in the past six months and the firm is making notable progress in the US. This includes the establishment of a processing agreement with Community Tissue Services, one of the USA's largest tissue banks, to produce DermaPure, the firm's human decellularised dermis product for chronic wounds and is on track for launch next year.

On Wednesday, October 30, we are in London, at the Chesterfield Mayfair hotel, with Atlantic Coal (LON:ATC),Canada Fluorspar (CVE:CFI) and North River Resources (LON:NRRP).

To register for this event, please click HERE.

Atlantic Coal has just exercised its lease option over the Pott & Bannon coal mine – a deal described by Best as “potentially transformational”.

And there could be more acquisitions in the pipeline, with the company on the lookout for new high quality mining sites in Pennsylvania to help it reach its goal of becoming a major producer in the US state.

Barney Corrigan, project development officer, is joining us to update on current progress and how it will achieve its ambitions.

Toronto-listed Canadian Fluorspar is positioning itself as a significant producer of fluorspar – a somewhat niche mineral described by some as the most important mineral you’ve never heard of.

It is an essential ‘feedstock’ for the chemical and metal alloy industry – it is an ingredient in products as diverse as anesthetics, non-stick coatings, fire retardant clothing, electrical components, aluminium and steel.

Internationally it is estimated that 5.6mln tonnes of fluorspar is consumed each year, a market that’s valued at around US$1.6bn.

Working out of St Lawrence, in Newfoundland, Canada, the junior mine developer is reactivating existing underground mines as well as expanding processing and infrastructure in order to produce between 120,000 and 180,000 tonnes of fluorspar concentrate per year.

Lindsay Gorrill, CEO & president, will be present to tell investors more about this exciting opportunity.

North River Resources (LON:NRRP) has worked over the historical data and found the Namib mine produced around 700,000 tons of ore between 1969 and 1991, plus more than 100,000 tons of lead and zinc concentrate, and more than 1mln ounces of silver.

A recent down-hole survey also indicated mineralisation at over 350m below the surface. 

Work now will focus upgrading the project’s existing JORC resource as part of the work on the feasibility study.

Martin French, managing director, will be joining us. 

Both events start at 6pm. Please join us at 5.45pm to allow for a prompt 6:00pm start. 

Each company has approximately 30 minutes to give a short presentation and for Q&A. Followed by the 'Champagne Raffle' where 6 lucky guests will win a bottle each.

The evening will end with a  complimentary bar and an assortment of the finest hot & cold canapes, giving you the opportunity to speak with the directors and other investors.

Quick facts: Tissue Regenix Group PLC

Price: 0.3326 GBX

Market: AIM
Market Cap: £23.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...


Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

6 min read